NCT02719977: A Phase I/II Study of CX5461

NCT02719977
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Any breast cancer type is eligible for Phase 1; Any breast cancer type with germline (inherited) BRCA1/2 mutations is eligible for the Phase 1 Expansion
Exclusions: 
https://ClinicalTrials.gov/show/NCT02719977

Comments are closed.

Up ↑